Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh Ellis

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Epigenomes|September 22, 2022
Polycomb Directed Cell Fate Decisions in Development and CancerBeatriz German, Leigh Ellis
Pharmaceuticals (Basel, Switzerland)|December 15, 2010
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesLeigh Ellis, Roberto Pili
Urologic Oncology|February 4, 2018
Epigenetic reprogramming: A key mechanism driving therapeutic resistanceAnjali V Sheahan, Leigh Ellis
Epigenomics|July 31, 2013
Histone modifications: implications in renal cell carcinomaSwathi Ramakrishnan, Leigh Ellis, Roberto Pili
Cancer Letters|December 30, 2008
Targeting tumor angiogenesis with histone deacetylase inhibitorsLeigh Ellis, Hans Hammers, Roberto Pili
Molecular Cancer Therapeutics|June 11, 2009
Epigenetics in cancer: targeting chromatin modificationsLeigh Ellis, Peter W Atadja, Ricky W Johnstone
Molecular & Cellular Oncology|April 13, 2017
Evasion of targeted cancer therapy through stem-cell-like reprogrammingKristine M Wadosky, Leigh Ellis, David W Goodrich
Critical Reviews in Oncogenesis|August 22, 2022
Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate CancerJagpreet Singh Nanda, Praveen Koganti, Graziela Perri, et al.
Oncoscience|December 9, 2014
Generation of a syngeneic orthotopic transplant model of prostate cancer metastasisLeigh Ellis, Kristin Lehet, ShengYu Ku, et al.
Oncotarget|October 6, 2017
miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growthShawn M Egan, Ellen Karasik, Leigh Ellis, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Epigenomes|September 22, 2022
Polycomb Directed Cell Fate Decisions in Development and CancerBeatriz German, Leigh Ellis
Pharmaceuticals (Basel, Switzerland)|December 15, 2010
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesLeigh Ellis, Roberto Pili
Urologic Oncology|February 4, 2018
Epigenetic reprogramming: A key mechanism driving therapeutic resistanceAnjali V Sheahan, Leigh Ellis
Epigenomics|July 31, 2013
Histone modifications: implications in renal cell carcinomaSwathi Ramakrishnan, Leigh Ellis, Roberto Pili
Cancer Letters|December 30, 2008
Targeting tumor angiogenesis with histone deacetylase inhibitorsLeigh Ellis, Hans Hammers, Roberto Pili
Molecular Cancer Therapeutics|June 11, 2009
Epigenetics in cancer: targeting chromatin modificationsLeigh Ellis, Peter W Atadja, Ricky W Johnstone
Molecular & Cellular Oncology|April 13, 2017
Evasion of targeted cancer therapy through stem-cell-like reprogrammingKristine M Wadosky, Leigh Ellis, David W Goodrich
Critical Reviews in Oncogenesis|August 22, 2022
Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate CancerJagpreet Singh Nanda, Praveen Koganti, Graziela Perri, et al.
Oncoscience|December 9, 2014
Generation of a syngeneic orthotopic transplant model of prostate cancer metastasisLeigh Ellis, Kristin Lehet, ShengYu Ku, et al.
Oncotarget|October 6, 2017
miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growthShawn M Egan, Ellen Karasik, Leigh Ellis, et al.
Pageof 7